A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Public ClinicalTrials.gov record NCT04035434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Study identification
- NCT ID
- NCT04035434
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- CRISPR Therapeutics AG
- Industry
- Enrollment
- 93 participants
Conditions and interventions
Interventions
- CTX110 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 21, 2019
- Primary completion
- Oct 3, 2024
- Completion
- Oct 3, 2024
- Last update posted
- Oct 23, 2025
2019 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars Sinai | Los Angeles | California | 90048 | — |
| UCSF Medical Center | San Francisco | California | 94143 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Kansas | Westwood | Kansas | 66205 | — |
| Markey Cancer Center, University of Kentucky | Lexington | Kentucky | 40536 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University | St Louis | Missouri | 63130 | — |
| Roswell Park Cancer Insitute | Buffalo | New York | 14203 | — |
| Weill Cornell Medical College / New York Presbyterian Hospital | New York | New York | 10021 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Texas Transplant Institute | San Antonio | Texas | 78229 | — |
| Virginia Commonwealth University Massey Cancer Center | Richmond | Virginia | 23298 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04035434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 23, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04035434 live on ClinicalTrials.gov.